Table 2.
Association of HER2 status with clinicopathologic factors in breast cancer patients
| Variables | HER2 + N = 105(%) | HER2- N = 472(%) | p |
|---|---|---|---|
| Mean age ± SD | 48.6 ± 9.7 | 47.9 ± 11 | 0.568 |
| Menopausal | 0.929 | ||
| < 50 years | 56(53.3) | 276(58.5) | |
| ≥ 50 years | 49(46.7) | 196(41.5) | |
| Histologic type | |||
| IDC-NST | 91(86.7) | 393(83.3) | 0.666 |
| Lobular | 5(4.8) | 25(5.3) | |
| Other | 9(8.5) | 54(11.4) | |
| Tumor grade | 0.007* | ||
| I | 13(13.8) | 83(21.1) | |
| II | 70(74.5) | 224(57.0) | |
| III | 11(11.7) | 86(21.8) | |
| ER status | 0.137 | ||
| Positive | 64(61.0) | 250(53.0) | |
| Negative | 41(39.0) | 222(47.0) | |
| PR status | 0.396 | ||
| Positive | 47(44.8) | 190(40.3) | |
| Negative | 58(55.2) | 282(59.7) | |
| ER/PR status | 0.134 | ||
| ER/PR+ | 68(64.8) | 268(56.8) | |
| ER/PR- | 37(35.2) | 204(43.2) | |
ER Estrogen receptor, HER2 Human epidermal growth factor receptor 2, IDC-NST Invasive ductal carcinoma of no special type, PR Progesterone receptor, SD Standard deviation, p p value; (*): Statistically significant difference with p < 0.05